By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...
China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said ...
Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...
Shanghai: China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese ...
Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...
Pfizer cuts 2026 revenue forecast as COVID sales fade and patents expire. The firm bets on a monthly obesity drug and ...
Hangzhou Sciwind Biosciences Co., Ltd. (Sciwind Biosciences) today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation ...
Pharmaceutical company Pfizer said Friday it was blocking use of its drugs in lethal injections, which means all federally-approved drugmakers whose medications could be used for executions have now ...
SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results